Ivana Magovčević-Liebisch

Ivana is President and Chief Executive Officer of Draig Therapeutics. She is an accomplished pharmaceutical and biotechnology executive with over 25 years of senior management experience, leading companies across a wide range of strategic and operational functions.

Before joining Draig, Ivana served as President and CEO of Vigil Neuroscience, a company she founded, built and led until its acquisition by Sanofi in August 2025. Under her leadership, Vigil evolved from inception with early preclinical assets through IPO to a clinical-stage organization within 18 months. Ivana also raised more than $350 million while advancing Vigil’s lead candidates into clinical development, including the first clinical-stage small molecule TREM2 agonist for the potential treatment of Alzheimer’s disease.

Earlier in her career, Ivana served as EVP and Chief Business Officer at Ipsen where she was responsible for building the company’s pipeline through executing key strategic transactions. Previously, she was SVP and Head of Global Business Development for the specialty drug business at Teva Pharmaceutical Industries Ltd. Prior to Teva, Ivana held multiple executive roles at Dyax. She is a member of the Board of Directors for Acrivon Therapeutics, and Quanterix Corporation. Ivana is also active in the non-profit world, serving as a trustee at the Museum of Science (Boston) and the Boston Ballet, and as an overseer at Beth Israel Deaconess Medical Center.

Ivana holds a Ph.D. in Genetics from Harvard University and received her J.D. in High Technology Law from Suffolk University Law School. She graduated from Wheaton College with a B.A. in Biology and Chemistry.